StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Seres Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Seres Therapeutics's total assets was $101.59M at Jun 30, 2026. For fiscal 2025 it was $138.19M, down 1.2% from the year before. Over ten years it grew -4.4% a year on average. The highest annual figure on record is $358.60M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$138.19M-1.2%
FY2024Dec 31, 2024$139.81M-61.0%
FY2023Dec 31, 2023$358.60M+2.8%
FY2022Dec 31, 2022$348.78M-1.7%
FY2021Dec 31, 2021$354.86M+3.5%
FY2020Dec 31, 2020$342.94M+158.9%
FY2019Dec 31, 2019$132.44M+9.9%
FY2018Dec 31, 2018$120.47M-36.4%
FY2017Dec 31, 2017$189.52M-30.5%
FY2016Dec 31, 2016$272.65M+25.7%
FY2015Dec 31, 2015$216.90M+84.8%
FY2014Dec 31, 2014$117.35M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$101.59M-29.4%
Q1 FY2026Mar 31, 2026$117.62M-28.4%
Q4 FY2025Dec 31, 2025$138.19M-1.2%
Q3 FY2025Sep 30, 2025$143.47M-19.7%
Q2 FY2025Jun 30, 2025$143.80M-55.3%
Q1 FY2025Mar 31, 2025$164.18M-51.9%
Q4 FY2024Dec 31, 2024$139.81M-61.0%
Q3 FY2024Sep 30, 2024$178.74M-51.4%
Q2 FY2024Jun 30, 2024$321.73M-20.8%
Q1 FY2024Mar 31, 2024$341.26M+26.3%
Q4 FY2023Dec 31, 2023$358.60M+2.8%
Q3 FY2023Sep 30, 2023$367.70M+17.9%
Q2 FY2023Jun 30, 2023$406.39M+48.8%
Q1 FY2023Mar 31, 2023$270.19M-15.5%
Q4 FY2022Dec 31, 2022$348.78M-1.7%
Q3 FY2022Sep 30, 2022$311.87M-21.3%
Q2 FY2022Jun 30, 2022$273.20M+1.3%
Q1 FY2022Mar 31, 2022$319.89M+4.6%
Q4 FY2021Dec 31, 2021$354.86M+3.5%
Q3 FY2021Sep 30, 2021$396.29M+11.3%
Q2 FY2021Jun 30, 2021$269.65M+167.8%
Q1 FY2021Mar 31, 2021$305.70M+176.3%
Q4 FY2020Dec 31, 2020$342.94M+158.9%
Q3 FY2020Sep 30, 2020$356.20M+186.9%
Q2 FY2020Jun 30, 2020$100.68M-31.1%
Q1 FY2020Mar 31, 2020$110.62M+3.3%
Q4 FY2019Dec 31, 2019$132.44M+9.9%
Q3 FY2019Sep 30, 2019$124.15M+13.9%
Q2 FY2019Jun 30, 2019$146.09M+9.9%
Q1 FY2019Mar 31, 2019$107.04M-32.9%
Q4 FY2018Dec 31, 2018$120.47M-36.4%
Q3 FY2018Sep 30, 2018$109.04M-48.5%
Q2 FY2018Jun 30, 2018$132.95M-38.5%
Q1 FY2018Mar 31, 2018$159.43M-34.9%
Q4 FY2017Dec 31, 2017$189.52M-30.5%
Q3 FY2017Sep 30, 2017$211.88M-28.8%
Q2 FY2017Jun 30, 2017$216.34M–
Q1 FY2017Mar 31, 2017$244.85M–
Q4 FY2016Dec 31, 2016$272.65M–
Q3 FY2016Sep 30, 2016$297.51M–

More Seres Therapeutics figures

See a number that looks wrong?